Abstract
Purpose
To study the development of collateral vessels and new vessels according to the types of branch retinal vein occlusion (BRVO).
Methods
One hundred and nine eyes of 103 patients with branch retinal vein occlusion were divided into 4 groups by anatomical position of blockage site and pattern of neovascularization. fluorescein angiography was used to examine perfusion/ nonperfusion, size of obstruction site, distance between obstruction site and optic disc (or macula). We compared initial visual acuity and final visual acuity.
Results
there was no statistically significant difference between group in size, between the obstruction site and the optic disc, between the obstruction site and macula. Collateral vessels occurred in major vessel obstruction (MVO) and major vessel and macula obstruction (MVMO) more than in macula obstruction (MO) and peripheral vessel obstruction (PV). Collateral vessels occurred 50 eyes in patients with macula edema and new vessels occurred 36 eyes in patients with macula edema. In collateral group, there was higher incidence of collateral vessels in ischemic type compared to nonischemic type and higher incidence of collateral vessels after laser photocoagulation. ischemic group with collateral vessels had better visual acuity prognosis than perfusion group with collateral vessels.
References
1. Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol. 1990; 109:298–302.
2. Christoffersen NL, Larsen M. Pathophysiology and hemodynamic of branch retinal vein occlusion. Ophtha-mology. 1999; 106:2054–62.
3. Ryan SJ. Retina. 4th. Vol. 2. St Louis: The C.V Mosby Company;2006. p. 1349–54.
5. Raitta C. Central venous and retinal venous occlusion. Acta Ophthalmol. 1965; 83:1–123.
6. Na KS, Yoon HM, Ji NC. A study on arteriovenous crossing sites in branch retinal vein occlusion. J Korean Ophthalmol Soc. 1992; 33:148–53.
7. Park NG, Park YH, Hahn DK. Risk factors and clinical course of bilateral branch retinal vein occlusion. J Korean Ophthalmol Soc. 1995; 36:1493–7.
8. Lee DY, Lee SH. Clinical research on the branch retinal vein occlusion. 1989; 30:933–42.
9. Appiah AP, Trempe CL. Risk factors associated with branch vs central retinal vein occlusion. Ann Ophthalmol. 1989; 21:153–5. 7.
10. Gutman FA. Evaluation of a patient with central retinal vein occlusion. Ophthalmology. 1983; 90:481–3.
11. Klein BA, Olwin JH. A survey on the pathogenesis of retinal vein occlusion. Arch Ophthalmol. 1956; 56:207–47.
12. Lee DY, Lee SH. Clinical research on the branch retinal vein occlusion. J Korean Ophthalmol Soc. 1989; 30:933–42.
13. Yoon YH, Lee JH. Clinical observation on retinal vein occlusion. J Korean Ophthalmol Soc. 1984; 25:477–84.
14. Kang KT, Kim YJ. Collateral circulation in the branch retinal vein occlusion. J Korean Ophthalmol Soc. 1991; 32:652–8.
15. David Orth. Color and fluorescein angiographic atlas of retinal vascular disorder. Baltimore: Williams & Wilkins;1984. p. 126–60.
16. Kanski JJ. Clinical ophthalmology. 6th. London: Butterworth International Edition;2007. p. 585–8.
17. Yang HN, Kim YJ, Kim JC, Shyn KH. Clinical evaluation for Branch retinal vein occlusion. J Korean Ophthalmol Soc. 1992; 33:599–604.
18. Duker JS, Brown GC. Anterior location of the crossing artery in branch retinal vein occlusion. Arch Ophthalmol. 1989; 107:998–1000.
19. Michaelsin IC. Textbook of the fundus of the eye. 3rd. Edinburgh: Churchil Livingston;1980. p. 216–43.
20. Oshikiri M. Clinical study on retinal vein occlusion. Jpn J Ophthalmol. 1986; 90:41–51.
22. Branch Retinal Vein Occlusion Group Argon laser photocoagulation for macular edema in branch retinal vein occlusion. Am J Ophthalmol. 1986; 98:271–82.
23. Guttman FA. Macular edema in branch retinal vein occlusion. Trans Am Acad Ophthalmol Otolaryngol. 1977; 83:488–95.
24. Kwon OW, Kim JS, Hong YJ, Kim HB. Size of capillary nonperfusion and their prognosis on branch retinal vein occlusion patients. J Korean Ophthalmol Soc. 1993; 34:1162–6.
Table 1.
Characteristics | No. of patients | Total or (%) | |||
---|---|---|---|---|---|
Male | Female | ||||
Age (year) | 30-39 | 1 | 1 | 2 | |
40-49 | 10 | 0 | 10 | ||
50-59 | 11 | 20 | 31 | ||
60-69 | 8 | 23 | 31 | ||
70-79 | 6 | 17 | 23 | ||
80- | 2 | 4 | 6 | ||
Total | 38 | 65 | 103 | ||
Affected eye | Right | 5 | 52 | (50.5) | |
Left | 4 | 45 | (43.7) | ||
Bilateral | 6 | (5.8) | |||
Location of BRVO | Superotemporal | 7 | 78 | (71.6) | |
Inferotemporal | 2 | 25 | (22.9) | ||
Superonasal | 5 | (4.6) | |||
Inferonasal | 1 | (0.9) | |||
Affected order | First order | 7 | 75 | (68.8) | |
Second order | 3 | 34 | (31.2) | ||
Systemic disease | Hypertension | 4 | 48 | (46.7) | |
Diabetes mellitus | 9 | (8.3) | |||
Hypertension+Diabetes mellitu | us | 6 | (5.5) | ||
PSVT∗ | 1 | (0.9) | |||
No disease | 51 | (49.5) |
Table 2.
Characteristics | Group | No. of patients (%) |
---|---|---|
according to site of blockage | Group A∗† | 37 (33.9%) |
Group B† | 42 (38.5%) | |
Group C‡ | 13 (11.9%) | |
Group D§ | 17 (15.6%) | |
Neovascularization | Group Ⅰ (collateral vessels only) | 44 (40.4%) |
Group Ⅱ (new vessels only) | 27 (24.8%) | |
Group Ⅲ (collateral vessels+new vessels) | 18 (16.5%) | |
Group Ⅳ (no neovasularization) | 20 (18.3%) |
Table 3.
Group Ⅰ∗ | Group Ⅱ† | Group Ⅲ‡ | Group Ⅳ§ | P value | |
---|---|---|---|---|---|
Obstruction site | 1.08±0.14 | 1.0±0.19 | 0.281 | ||
Obstruction size | 4.51±0.38 | 3.65±0.66 | 0.153 | ||
Macula invasion | 0.79±0.17 | 1.18±0.24 | 0.209 | ||
Non-perfusion (67/109 eyes) | 33/67 (49.3%) | 18/67 (26.9%) | 9/67 (13.4%) | 7/67 (10.4%) | 0.005 |
Perfusion (42/109 eyes) | 11/42 (26.2%) | 9/42 (21.4%) | 9/42 (21.4%) | 13/42 (31.0%) | 0.183 |
Laser therapy | 31/66 (47.0%) | 10/66 (15.2%) | 14/66 (21.2%) | 11/66 (16.6%) | 0.014 |
IVTA | 19/58 (32.7%) | 19/58 (32.7%) | 13/58 (22.5%) | 7/58 (12.1%) | 0.017 |
Table 4.
Group A∗ (%) | Group B† (%) | Group C‡ (%) | Group D§ (%) | P value | |
---|---|---|---|---|---|
Collateral | 24/37 (64.9%) | 28/42 (66.7%) | 3/13 (23.1%) | 6/17 (35.3%) | 0.008 |
New vessels | 9/37 (24.3%) | 23/42 (54.8%) | 6/13 (46.2%) | 9/17 (52.9%) | 0.008 |
Macular edema | Macular edema | P value | |||
Collateral | 50/77 (64.9%) | No col | llateral | 27/77 (35.1%) | 0.003 |
New vessels | 36/77 (46.8%) | No new | vessels | 41/77 (53.2%) | 0.235 |
P | Perfusion type | ||||
Initial visual acuit | ty Final visu | ual acuity | Visual difference | P value | |
Collateral | -1.58±0.25 | -1.26 | 6±0.26 | 0.25±0.05 | 0.260 |
New vessels | -2.00±0.29 | -1.66 | 6±0.26 | 0.38±0.04 | 0.162 |
No | onperfusion type | ||||
Initial visual acuit | ty Final visu | ual acuity | Visual difference | P value | |
Collateral | -2.45±0.25 | -1.01 | 1±0.16 | 1.38±0.08 | 0.000 |
New vessels | -1.72±0.29 | -1.22 | 2±0.34 | 0.46±0.07 | 0.067 |